Kala’s dry eye treatment nears potential US launch before 2021

Video

Susan Coultas, PhD, and Preeya Gupta, MD, discuss Kala Pharmaceuticals’ dry eye product candidate in a poster presentation during the 2020 Women in Ophthalmology virtual summer symposium.


Susan Coultas, PhD (top left), and Preeya Gupta, MD (bottom, middle) , discuss Kala Pharmaceuticals’ dry eye product candidate in a poster presentation—“Safety and Efficacy of KPI-121 0.25% for the Short-Term Treatment of Signs and Symptoms of Dry Eye Disease in Three Large Multicenter Randomized Controlled Trials”—during the 2020 Women in Ophthalmology virtual summer symposium with Sheryl Stevenson, group editorial director, Ophthalmology Times®.

Recent Videos
This series features 1 KOL.
This series features 1 KOL.
This series features 1 KOL.
Alice Epitropoulos, MD, and Laura M. Periman, MD
Alice Epitropoulos, MD, and Laura M. Periman, MD
Video 2 - 1 KOL is featured in, "Advances in Technology for SMILE procedure"
Video 1 - 1 KOL is featured in, "Overview of Small Incision Lenticule Extraction (SMILE)"
Vicki Chan, MD, shares pearls for leveraging the power of social media in health care
EyeCon 2024: Peter J. McDonnell, MD, marvels on mentoring, modern technology, and ophthalmology’s future
EyeCon Co-chair Oluwatosin U. Smith, MD: Passion for Research and Education Drives Her Commitment to Ophthalmology
© 2024 MJH Life Sciences

All rights reserved.